Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
Mol Diagn Ther. 2019 Oct;23(5):603-614. doi: 10.1007/s40291-019-00413-1.
In recent years, there has been a great deal of interest in the identification and validation of blood-based biomarkers for clinical use in chronic obstructive pulmonary disease (COPD). We now have panels of blood biomarkers that potentially hold great promise as they show statistically significant associations with COPD, but biomarkers for the diagnosis of COPD remain elusive. In fact, they are yet to demonstrate sufficient accuracy to be accepted in clinical use, and many are not specific to COPD but more related to inflammation (e.g. interleukin-6) or associated with other chronic diseases such as diabetes (e.g. soluble receptor for advanced glycation endproducts [sRAGE]). Although no single blood-based biomarker has demonstrated clinical utility for either the diagnosis or progression of COPD, it has been suggested that combinations of individual markers may provide important diagnostic or prognostic information; however, the interpretation of COPD biomarker results still requires thought and many questions remain unanswered.
近年来，人们对鉴定和验证用于慢性阻塞性肺疾病（COPD）临床应用的血液生物标志物产生了浓厚的兴趣。我们现在有一系列的血液生物标志物，它们具有很大的潜力，因为它们与 COPD 有统计学上显著的关联，但用于 COPD 诊断的生物标志物仍然难以捉摸。事实上，它们还没有表现出足够的准确性，无法被临床接受，而且许多标志物都不是特异性的 COPD，而是更多地与炎症（例如白细胞介素-6）相关，或者与其他慢性疾病（如糖尿病）相关（例如晚期糖基化终产物的可溶性受体 [sRAGE]）。虽然没有任何单一的血液生物标志物在 COPD 的诊断或进展方面表现出临床实用性，但有人认为单个标志物的组合可能提供重要的诊断或预后信息；然而，对 COPD 生物标志物结果的解释仍然需要思考，并且还有许多问题没有得到解答。
